Related Experiment Videos
Bambuterol: a new long acting bronchodilating prodrug
J S Vilsvik1, O Langaker, G Persson
1Department of Pulmonary Disease, Regional Hospital, University of Trondheim, Norway.
Annals of Allergy
|April 1, 1991
Summary
Bambuterol, a long-acting asthma medication, effectively improved lung function for 24 hours at a 20-mg dose. Lower doses of 5 and 10 mg did not show significant benefits, with few side effects reported.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Clinical Trials
Background:
- Asthma management requires effective bronchodilators.
- Terbutaline is a beta-2 agonist used for asthma.
- Bambuterol is a prodrug designed for sustained release of terbutaline.
Purpose of the Study:
- To evaluate the efficacy and safety of bambuterol in asthma patients.
- To determine the optimal dosage for sustained bronchodilation.
Main Methods:
- A randomized, double-blind, crossover study design.
- Patients received bambuterol in 5, 10, or 20-mg doses once nightly.
- Pulmonary function tests were used to assess efficacy over 24 hours.
Main Results:
- The 20-mg dose of bambuterol significantly improved pulmonary function for 24 hours.
- Doses of 5 mg and 10 mg did not demonstrate significant improvements.
- Adverse events were minimal across all tested dosages.
Conclusions:
- Bambuterol at 20 mg once daily is an effective treatment for improving pulmonary function in asthma.
- Lower doses may not provide adequate therapeutic benefit.
- Bambuterol demonstrates a favorable safety profile for asthma management.